In this study, we selected ovarian cancer patients who were treated in our hospital from January to December 2020 to conduct relevant clinical trials to explore the clinical efficacy of CX3CL1/CX3CR1 gene polymorphisms in carboplatin-treated patients. Here, CX3CR1 is linked to ovarian carcinoma.